obesity drug news today glp-1 september 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 World Health Organization recommends GLP-1

Assessment of pharmacological responses to an anti-diabetic drug in a new obese type 2 diabetic rat model

Both big Weight loss drugs have open law suits in US

GLP-1 RA Addition to Background DPP-4 Inhibitor GLP-1 RAs and DPP-4 inhibitors both work to augment the impaired incretin response present in people with T2D

You are not obligated to accept one doctor assessment as final

7 Long-acting liraglutide was approved in 2009 and 2010 by the European Medicines Agency and FDA, respectively, followed by lixisenatide (2013 EMA, 2016 FDA), albiglutide (2014 for both EMA and FDA) and dulaglutide (2014 for both EMA and FDA) 8 On December 5, 2017, semaglutide was approved in the USA for its use as subcutaneous injection, while in Europe, semaglutide was approved by the EMA on February 8, 2018